TickerFacts.

A business in context

TNGX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-09-01 · 0001193125-26-381853

  2. 8-K · Current report

    Report date 2026-08-11 · 0001193125-26-344997 · Items 8.01,9.01

  3. 8-K · Current report

    Report date 2026-08-11 · 0001193125-26-343434 · Items 2.02,9.01

  4. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-343424

  5. 8-K/A · Current report

    Report date 2026-07-31 · 0001193125-26-339070 · Items 5.02,7.01,9.01

  6. 8-K · Current report

    Report date 2026-07-31 · 0001193125-26-338480 · Items 5.02

  7. 4 · Ownership change

    Report date 2026-08-03 · 0001193125-26-335002

  8. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-295124

  9. 4 · Ownership change

    Report date 2026-06-19 · 0001193125-26-279871

  10. 8-K · Current report

    Report date 2026-06-19 · 0001193125-26-279788 · Items 5.02,9.01

  11. 8-K · Current report

    Report date 2026-06-09 · 0001193125-26-266078 · Items 1.01,9.01

  12. 4 · Ownership change

    Report date 2026-06-05 · 0001193125-26-262227

  13. 4 · Ownership change

    Report date 2026-06-05 · 0001193125-26-262205

  14. 4 · Ownership change

    Report date 2026-06-05 · 0001193125-26-262191

  15. 4 · Ownership change

    Report date 2026-06-05 · 0001193125-26-262172

  16. 8-K · Current report

    Report date 2026-06-08 · 0001193125-26-260679 · Items 7.01,8.01,9.01

  17. 8-K · Current report

    Report date 2026-06-04 · 0001193125-26-257760 · Items 5.07

  18. 8-K · Current report

    Report date 2026-05-13 · 0001193125-26-221677 · Items 2.02,5.02,9.01

  19. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-221656

  20. 8-K · Current report

    Report date 2026-05-07 · 0001193125-26-213491 · Items 5.02,9.01

  21. DEF 14A · Proxy statement

    Report date 2026-04-16 · 0001193125-26-160287

  22. 8-K · Current report

    Report date 2026-04-10 · 0001193125-26-156127 · Items 5.02,7.01,9.01

  23. 8-K · Current report

    Report date 2026-03-05 · 0001193125-26-092535 · Items 2.02,9.01

  24. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-092518

  25. 8-K · Current report

    Report date 2026-01-07 · 0001193125-26-007086 · Items 2.02,5.02,7.01,9.01

  26. 8-K · Current report

    Report date 2026-01-02 · 0001193125-26-001495 · Items 5.02,9.01

  27. 8-K · Current report

    Report date 2025-11-18 · 0001193125-25-290679 · Items 1.01,1.02

  28. 8-K · Current report

    Report date 2025-11-04 · 0001193125-25-263684 · Items 2.02,9.01

  29. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-263680

  30. 8-K · Current report

    Report date 2025-10-23 · 0001193125-25-249302 · Items 1.01,3.02,9.01

  31. 8-K · Current report

    Report date 2025-10-23 · 0001193125-25-247658 · Items 2.02,8.01,9.01

  32. 8-K · Current report

    Report date 2025-08-21 · 0001193125-25-187680 · Items 5.02

  33. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-102392

  34. 8-K · Current report

    Report date 2025-08-05 · 0000950170-25-102387 · Items 2.02,9.01

  35. 8-K · Current report

    Report date 2025-06-05 · 0001193125-25-137032 · Items 5.03,5.07,9.01

  36. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-068549

  37. 8-K · Current report

    Report date 2025-05-12 · 0000950170-25-068546 · Items 2.02,9.01

  38. DEF 14A · Proxy statement

    Report date 2025-04-21 · 0000950170-25-056230

  39. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-028353

  40. 8-K · Current report

    Report date 2022-08-10 · 0000950170-25-028345 · Items 2.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 6 transaction rows6SGrant / award: 14 transaction rows14AExercise / conversion: 8 transaction rows8MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

28 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-19
2026-06-23
Azelby RobertA · Grant / award
Acquired
Common Stock5740.00.0
2026-06-19
2026-06-23
Azelby RobertA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
35910.00.0
2026-06-05
2026-06-08
Ketchum John BA · Grant / award
Acquired
Common Stock4000.00.0
2026-06-05
2026-06-08
Ketchum John BA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
25000.00.0
2026-06-05
2026-06-08
Calhoun Lesley AnnA · Grant / award
Acquired
Common Stock4000.00.0
2026-06-05
2026-06-08
Calhoun Lesley AnnA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
25000.00.0
2026-06-05
2026-06-08
Rothenberg MaceA · Grant / award
Acquired
Common Stock4000.00.0
2026-06-05
2026-06-08
Rothenberg MaceA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
25000.00.0
2026-06-05
2026-06-08
Lee SungA · Grant / award
Acquired
Common Stock570.00.0
2026-06-05
2026-06-08
Lee SungA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
3570.00.0
2026-06-01
2026-06-03
Crystal AdamM · Exercise / conversion
Acquired
Common Stock27000.05.2
2026-06-01
2026-06-03
Crystal AdamS · Sale
Disposed
Common Stock20860.023.06
2026-06-01
2026-06-03
Crystal AdamS · Sale
Disposed
Common Stock6140.022.25
2026-06-01
2026-06-03
Crystal AdamM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
27000.00.0
2026-05-01
2026-05-05
Crystal AdamS · Sale
Disposed
Common Stock25900.021.19
2026-05-01
2026-05-05
Crystal AdamM · Exercise / conversion
Acquired
Common Stock27000.05.2
2026-05-01
2026-05-05
Crystal AdamS · Sale
Disposed
Common Stock1100.022.0
2026-05-01
2026-05-05
Crystal AdamM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
27000.00.0
2026-05-01
2026-05-05
Gall MatthewA · Grant / award
Acquired
Common Stock40000.00.0
2026-05-01
2026-05-05
Gall MatthewA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
240000.00.0
2026-04-29
2026-05-01
Lee SungA · Grant / award
Acquired
Common Stock12300.00.0
2026-04-29
2026-05-01
Lee SungA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
5200.00.0
2026-04-15
2026-04-16
Crystal AdamM · Exercise / conversion
Acquired
Common Stock38460.05.2
2026-04-15
2026-04-16
Crystal AdamS · Sale
Disposed
Common Stock38460.025.0
2026-04-15
2026-04-16
Crystal AdamM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
38460.00.0
2026-04-01
2026-04-02
Crystal AdamS · Sale
Disposed
Common Stock27000.021.2
2026-04-01
2026-04-02
Crystal AdamM · Exercise / conversion
Acquired
Common Stock27000.05.2
2026-04-01
2026-04-02
Crystal AdamM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
27000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001819133Tango Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Tango Therapeutics (United States) · alias · wikidata
  • BCTG Acquisition Corp. · former SEC name · 2020-07-30 to 2021-08-09

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$42.07M$44.78M
2023-12-31$36.53M$40.03M
2022-12-31$24.86M$28.36M
2021-12-31$37.04M$45.64M
2020-12-31$7.66M$9.88M

Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing

Explore the CPI history ↗